Recently patented and promising ORL-1 ligands: where have we been and where are we going?

Bibliography

• Mollereau C, Parmentier M, Mailleux P, ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 1994;341(1):33-8
   PubMed Web of Science ®Google Scholar
• Civelli O. The orphanin FQ/nociceptin (OFQ/N) system. Results Probl Cell Differ 2008;46:1-25
   PubMedGoogle Scholar
• Mogil JS, Pasternak GW. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 2001;53(3):381-415
   PubMed Web of Science ®Google Scholar
• Meunier JC. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. Eur J Pharmacol 1997;340(1):1-15
   PubMed Web of Science ®Google Scholar
• Meunier JC, Mollereau C, Toll L, Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995;377(6549):532-5
   PubMed Web of Science ®Google Scholar
• Reinscheid RK, Nothacker HP, Bourson A, Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 1995;270(5237):792-4
   PubMed Web of Science ®Google Scholar
• Foord SM, Bonner TI, Neubig RR, International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev 2005;57:279-88
   PubMed Web of Science ®Google Scholar
• New DC, Wong YH. The ORL1 receptor: molecular pharmacology and signaling mechanisms. Neurosignals 2002;11(4):197-212
   PubMedGoogle Scholar
• Butour JL, Moisand C, Mazarguil H, Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids. Eur J Pharmacol 1997;321(1):97-103
   PubMed Web of Science ®Google Scholar
• Chan JS, Yung LY, Lee JW, Pertussis toxin-insensitive signaling of the ORL1 receptor: coupling to Gz and G16 proteins. J Neurochem 1998;71(5):2203-10
   PubMed Web of Science ®Google Scholar
• Matthes H, Seward EP, Kieffer B, Functional selectivity of orphanin FQ for its receptor coexpressed with potassium channel subunit in Xenopus laevis oocytes. Mol Pharmacol 1996;50:447-50
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kobayashi K, Kobayashi T, Functional coupling of the nociceptin/orphanin FQ receptor with the G protein-activated K+ (GIRK) channel. Mol Brain Res 1997;45:117-26
   PubMedGoogle Scholar
• Vaughan CW, Christie MJ. Increase by the ORL1 receptor (opioid receptor-like 1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurons. Br J Pharmacol 1996;117:1609-11
   PubMed Web of Science ®Google Scholar
• Fukuda K, Shoda T, Morikawa H, Activation of mitogen-activated protein kinase by the nociceptin receptor expressed in Chinese hamster ovary cells. FEBS Lett 1997;412(2):290-4
   PubMed Web of Science ®Google Scholar
• Neal CR Jr, Mansour A, Reinscheid R, Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurol 1999;406(4):503-47
   PubMed Web of Science ®Google Scholar
• Neal CR Jr, Mansour A, Reinscheid R, Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol 1999;412(4):563-605
   PubMed Web of Science ®Google Scholar
• Mollereau C, Simons MJ, Soularue P, Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. Proc Natl Acad Sci USA 1996;93(16):8666-70
   PubMed Web of Science ®Google Scholar
• Nothacker HP, Reinscheid RK, Mansour A, Primary structure and tissue distribution of the orphanin FQ precursor. Proc Natl Acad Sci USA 1996; 93(16):8677-82
   PubMed Web of Science ®Google Scholar
• Wang JB, Johnson PS, Imai Y, cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett 1994;348:75-9
   PubMed Web of Science ®Google Scholar
• Available from: www.patentstorm.com
   Google Scholar
• Calo' G, Bigoni R, Rizzi A, Nociceptin/orphanin FQ receptor ligands. Peptides 2000;21(7):935-47
   PubMed Web of Science ®Google Scholar
• Bojnik E, Farkas J, Magyar A, Selective and high affinity labeling of neuronal and recombinant nociceptin receptors with the hexapeptide radioprobe [(3)H]Ac-RYYRIK-ol. Neurochem Int 2009;55(7):458-66
   PubMed Web of Science ®Google Scholar
• Calo' G, Guerrini R, Rizzi A, Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol 2000; 129(7):1261-83
   PubMed Web of Science ®Google Scholar
• Calò G, Rizzi A, Bogoni G, The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur J Pharmacol 1996;311(1):R3-5
   Web of Science ®Google Scholar
• Okada K, SUjaku T, Chuman Y, Highly potent nociceptin analog containing the Arg-Lys triple repeat. Biochem Biophys Res Commun 2000;278(2):493-8
   PubMed Web of Science ®Google Scholar
• Rizzi A, Spagnolo B, Wainford RD, In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides 2007;28(6):1240-51
   PubMed Web of Science ®Google Scholar
• Guerrini R, Salvadori S, Calo G, Highly potent full and partial agonists and antagonists of the nociception/orphanin FQ receptor. WO2006087340A2; 2006
   Google Scholar
• Berger H, Bigoni R, Albrecht E, The nociceptin/orphanin FQ receptor ligand acetyl-YYRIK-amide exhibits antagonistic and agonistic properties. Peptides 2000;21(7):1131-9
   PubMed Web of Science ®Google Scholar
• Dooley CT, Spaeth CG, Berzetei-Gurske IP, Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther 1997;283(2):735-41
   PubMed Web of Science ®Google Scholar
• Barlocco D, Cignarella G, Giardina GA, The opioid-receptor-like 1 (ORL-1) as a potential target for new analgesics. Eur J Med Chem 2000;35(3):275-82
   PubMed Web of Science ®Google Scholar
• Guerrini R, Calo G, Rizzi A, A new selective antagonist for the nociception receptor. Brit J Pharmacol 1998;123:163-5
   PubMed Web of Science ®Google Scholar
• Guerrini R, Calo G, Rizzi A, Address and message sequences for the nociception receptor: a structure-activity study of nociception-(1-13)-peptide amide. J Med Chem 1997;40:1789-93
   PubMed Web of Science ®Google Scholar
• Salvadori S, Guerrini R, Calo G, Structure-activity studies on nociceptin/orphanin FQ: from full agonist, to partial agonist, to pure antagonist. Farmaco 1999;54(11-12):810-25
   PubMedGoogle Scholar
• Hashimoto Y, Caló G, Guerrini R, Antagonistic effects of [Nphe1]nociceptin(1-13)NH2 on nociceptin receptor mediated inhibition of cAMP formation in Chinese hamster ovary cells stably expressing the recombinant human nociceptin receptor. Neurosci Lett 2000;278(1-2):109-12
   PubMed Web of Science ®Google Scholar
• Calo G, Rizzi A, Rizzi D, [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol 2002;136(2):303-11
   PubMed Web of Science ®Google Scholar
• Fioravanti B, Vanderah TW. The ORL-1 receptor system: are there opportunities for antagonists in pain therapy? Curr Top Med Chem 2008;8(16):1442-51
   PubMed Web of Science ®Google Scholar
• Chang M, Peng YL, Dong SL, Structure-activity studies on different modifications of nociceptin/orphanin FQ: identification of highly potent agonists and antagonists of its receptor. Regul Pept 2005; 130(3):116-22
   PubMedGoogle Scholar
• Peng YL, Chang M, Dong SL, Novel potent agonist [(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 and antagonist [Nphe1,(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 of nociceptin/orphanin FQ receptor. Regul Pept 2006;134(2-3):75-81
   PubMedGoogle Scholar
• Röver S, Adam G, Cesura AM, High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor. J Med Chem 2000;43(7):1329-38
   PubMed Web of Science ®Google Scholar
• Jenck F, Wichmann J, Dautzenberg FM, A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1:anxiolytic profile in the rat. Proc Natl Acad Sci USA 2000;97(9):4938-43
   PubMed Web of Science ®Google Scholar
• Wichmann J, Adam G, Röver S, Synthesis of (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties. Eur J Med Chem 2000;35(9):839-51
   PubMed Web of Science ®Google Scholar
• Shoblock JR. The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity. CNS Drug Rev 2007;13(1):107-36
   PubMedGoogle Scholar
• Schering Corp. High Affinity ligands for nociception receptor ORL1. US7094784; 2006
   Google Scholar
• Schering Corp. High Affinity ligands for nociception receptor ORL1. US7485650; 2009
   Google Scholar
• Kawamoto H, Ozaki S, Itoh Y, Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). J Med Chem 1999;42(25):5061-3
   PubMed Web of Science ®Google Scholar
• Chiou LC, Liao LL, Fan PC, Nociceptin/ orphanin FQ receptors: pharmacology and clinical implications. Curr Drug Targets 2007;8:117-35
   PubMed Web of Science ®Google Scholar
• Satoh A, Sagara T, Sakoh H, Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1′-cyclopropan]-3-ylmethyl]piperidine as clinical candidate. J Med Chem 2009;52(14):4091-4
   PubMed Web of Science ®Google Scholar
• Goto Y, Arai-Otsuki S, Tachibana Y, Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. J Med Chem 2006;49(3):847-9
   PubMed Web of Science ®Google Scholar
• Fischetti C, Camarda V, Rizzi A, Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist compound 24. Eur J Pharmacol 2009;614(1-3):50-7
   PubMed Web of Science ®Google Scholar
• Liao YY, Trapella C, Chiou LC. 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl}pyrrolidine-2carboxamide (compound 24) antagonizes NOP receptor-mediated potassium channel activation in rat periaquaductal gray slices. Eur J Pharmacol 2009;606:84-9
   PubMedGoogle Scholar
• Lambert DG. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov 2008;7(8):694-710
   PubMed Web of Science ®Google Scholar
• Shinkai H, Ito T, Iida T, 4-Aminoquinolines: novel nociceptin antagonists with analgesic activity. J Med Chem 2000;43(24):4667-77
   PubMed Web of Science ®Google Scholar
• Yamada H, Nakamoto H, Suzuki Y, Pharmacological profiles of a novel opioid receptor-like1 (ORL(1)) receptor antagonist, JTC-801. Br J Pharmacol 2002;135(2):323-32
   PubMed Web of Science ®Google Scholar
• Zaveri N. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci 2003;73(6):663-78
   PubMed Web of Science ®Google Scholar
• Japan Tobacco Co. Amide derivatives and nociception antagonists. US6410561B1; 2002
   Google Scholar
• Japan Tobacco Co. Amide derivatives and nociception antagonists. US2006030565; 2006
   Google Scholar
• Zaratin PF, Petrone G, Sbacchi M, Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). J Pharmacol Exp Ther 2004;308(2):454-61
   PubMed Web of Science ®Google Scholar
• Spagnolo B, Carrà G, Fantin M, Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies. J Pharmacol Exp Ther 2007;321(3):961-7
   PubMed Web of Science ®Google Scholar
• Trapella C, Guerrini R, Piccagli L, Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorg Med Chem 2006;14(3):692-704
   PubMed Web of Science ®Google Scholar
• Marti M, Trapella C, Morari M. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA. J Neurochem 2008;107(6):1683-96
   PubMed Web of Science ®Google Scholar
• Woodcock J, Witter J, Dionne RA. Stimulating the development of mechanism-based, individualized pain therapies. Nat Rev Drug Discov 2007;6(9):703-10
   PubMed Web of Science ®Google Scholar
• Purdue Pharma, L.P. Nociceptin anaglogs. US7563809; 2009
   Google Scholar
• Gruenenthal GmbH. Substituted 4-aminocyclohexanols. US7183436; 2007
   Google Scholar
• Gruenenthal GmbH. Spirocyclic cyclohexane compounds. US2005192333; 2005
   Google Scholar
• Gruenenthal GmbH. Spirocyclic cyclohexan derivatives. EP2062898 A2; 2009
   Google Scholar
• Gruenenthal GmbH. Use of morphine derivatives as medicaments for the treatment of neuropathic problems. US6476044 B1; 2002
   Google Scholar
• Gruenenthal GmbH. Cyclohexylurea compounds. US2005261358A1; 2005
   Google Scholar
• Nippon Shinyaku Co, Ltd. New physiologically active peptide. JP11021298; 1999
   Google Scholar
• Okana M, Mori K, Nippon Shinyaku Co., Ltd. Hetero cycle derivatives and drugs. US2003119855A1; 2003
   Google Scholar
• Okana M, Mori K, Nippon Shinyaku Co., Ltd. Quinazoline derivatives and drugs. US6794389B2; 2004
   Google Scholar
• Nippon Shinyaku Co., Ltd. Peptide derivatives and medicinal compositions. US7163921B2; 2007
   Google Scholar
• Stanford Research Institute. Agonist and antagonist ligands of the nociception receptor. WO2005060947A2; 2005
   Google Scholar
• Khroyan TV, Zaveri NT, Polgar WE, SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice. J Pharmacol Exp Ther 2007;320(2):934-43
   PubMed Web of Science ®Google Scholar
• Adapa ID, Toll L. Relationship between binding affinity and functional activity of nociceptin/orphanin FQ. Neuropeptides 1997;31(5):403-8
   PubMed Web of Science ®Google Scholar
• Zaveri N, Polgar WE, Olsen CM, Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. Eur J Pharmacol 2001;428(1):29-36
   PubMed Web of Science ®Google Scholar
• Wnendt S, Krüger T, Janocha E, Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol Pharmacol 1999;56(2):334-8
   PubMed Web of Science ®Google Scholar
• Spagnolo B, Calo G, Polgar WE, Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol 2008;153(3):609-19
   PubMed Web of Science ®Google Scholar
• Ciccocioppo R, Economidou D, Rimondini R, Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry 2007;61(1):4-12
   PubMed Web of Science ®Google Scholar
• European Patent Office. Available from: http://ep.espacenet.com/
   Google Scholar
• US Patent and Trademark Office. Available from: http://patft.uspto.gov/
   Google Scholar
• World Intellectual Property Organization. Available from: http://www.wipo.int/pctdb/en/index.jsp
   Google Scholar
• Euro Celtique SA. Nociceptin analogs. US2009156640A1; 2009
   Google Scholar
• Mono Biotech Lab AG. Use of a peptide as a therapeutic. WO2009046879A2; 2009
   Google Scholar
• Pfizer. Treatment of Urinary conditions including incontinence. WO2005117862A1; 2005
   Google Scholar
• Zealand Pharmaceuticals AS. Novel Peptide conjugates. US2003040472A1; 2003
   Google Scholar
• Uni Degli Studi di Ferrara, Morari M, Marti M. NOP receptor agonists for the treatment of L-DOPA induced dyskinesia. WO2008062296A2; 2008
   Google Scholar
• Bignan GC, Connelly PJ, Middleton SA. Recent advances towardthe discovery of ORL-1 agonists and antagonists. Expert Opin Ther Patents 2005;15(4):357-88
   Web of Science ®Google Scholar
• Heinricher MM. Nociceptin/orphanin FQ: pain, stress and neural circuits. Life Sci 2005;77(25):3127-32
   PubMed Web of Science ®Google Scholar
• Zeilhofer HU, Calò G. Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy? J Pharmacol Exp Ther 2003;306(2):423-9
   PubMed Web of Science ®Google Scholar
• Suaudeau C, Florin S, Meunier JC, Nociceptin-induced apparent hyperalgesia in mice as a result of the prevention of opioid autoanalgesic mechanisms triggered by the stress of an intracerebroventricular injection. Fundam Clin Pharmacol 1998;12(4):420-5
   PubMed Web of Science ®Google Scholar
• Rossi GC, Leventhal L, Pasternak GW. Naloxone sensitive orphanin FQ-induced analgesia in mice. Eur J Pharmacol 1996 311:R7-8
   PubMed Web of Science ®Google Scholar
• Heinricher MM, McGaraughty S, Grandy DK. Circuitry underlying antiopioid actions of orphanin FQ in the rostral ventromedial medulla. J Neurophysiol 1997;78(6):3351-8
   PubMed Web of Science ®Google Scholar
• Pan Z, Hirakawa N, Fields HL. A cellular mechanism for the bidirectional pain-modulating actions of orphanin FQ/nociceptin. Neuron 2000;26:515-22
   PubMed Web of Science ®Google Scholar
• Sakurada C, Sakurada S, Katsuyama S, Involvement of tachykinin NK1 receptors in nociceptin-induced hyperalgesia in mice. Brain Res 1999;841(1-2):85-92
   PubMed Web of Science ®Google Scholar
• Obara I, Przewlocki R, Przewlocka B. Spinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain in the rat. Pain 2005;116(1-2):17-25
   PubMed Web of Science ®Google Scholar
• Varty GB, Hyde LA, Hodgson RA, Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psychopharmacology (Berl) 2005;182(1):132-43
   PubMed Web of Science ®Google Scholar
• Chiou LC, Fan SH, Chuang KC, Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray. Ann NY Acad Sci 2004;1025:398-403
   PubMed Web of Science ®Google Scholar
• Chiou LC, Chuang KC, Wichmann J, Ro64-6198 [(1S,3aS)-8-(2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one] acts differently from nociceptin/orphanin FQ in rat periaquaductal gray slices. J Pharmacol Exp Ther 2004;311:645-51
   PubMed Web of Science ®Google Scholar
• Ko MC, Naughton NN, Traynor JR, Orphanin FQ inhibits capsaicin-induced thermal nociception in monkeys by activation of peripheral ORL1 receptors. Br J Pharmacol 2002;135(4):943-50
   PubMed Web of Science ®Google Scholar
• Ko MC, Wei H, Woods JH, Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies. J Pharmacol Exp Ther 2006;318(3):1257-64
   PubMed Web of Science ®Google Scholar
• Ko MC, Naughton NN. Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys. J Pain 2009;10(5):509-16
   PubMed Web of Science ®Google Scholar
• Ko MC, Woods JH, Fantegrossi WE, Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology 2009;34(9):2088-96
   PubMed Web of Science ®Google Scholar
• Hu E, Calo G, Guerrini R, Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain 2010;148:107-13
   PubMed Web of Science ®Google Scholar
• Ko MH, Kim YH, Woo RS, NeuroReport 2002;13(13):1631-3
   PubMed Web of Science ®Google Scholar
• Brooks H, Elton CD, Smart D, Identification of nociceptin in human cerebrospinal fluid: comparison of levels in pain and non-pain states. Pain 1998;78(1):71-3
   PubMed Web of Science ®Google Scholar
• Anderberg UM, Liu Z, Berglund L, Plasma levels on nociceptin in female fibromyalgia syndrome patients. Z Rheumatol 1998;57(Suppl 2):77-80
   PubMedGoogle Scholar
• Barnes TA, Lambert DG. Editorial III: Nociceptin/orphanin FQ peptide-receptor system: are we any nearer the clinic? Br J Anaesth 2004;93(5):626-8
   PubMed Web of Science ®Google Scholar
• Raffaeli W, Samolsky Dekel BG, Landuzzi D, Nociceptin levels in the cerebrospinal fluid of chronic pain patients with or without intrathecal administration of morphine. J Pain Symptom Manage 2006;32(4):372-7
   PubMed Web of Science ®Google Scholar
• Joseph T, Lee TL, Li C, Levels of neuropeptides nocistatin, nociceptin/orphanin FQ and their precursor protein in a rat neuropathic pain model. Peptides 2007;28(7):1433-40
   PubMed Web of Science ®Google Scholar
• Rizzi A, Bigoni R, Marzola G, The nociceptin/orphanin FQ receptor antagonist, [Nphe1]NC(1-13)NH2, potentiates morphine analgesia. Neuroreport 2000; 11(11):2369-72
   PubMed Web of Science ®Google Scholar
• Rizzi A, Nazzaro C, Marzola GG, Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences. Pain 2006;124(1-2):100-8
   PubMed Web of Science ®Google Scholar
• Scoto GM, Aricò G, Iemolo A, Involvement of the nociceptin/orphanin FQ-NOP receptor system in the ventrolateral periaqueductal gray following mechanical allodynia in chronic pain. Life Sci 2009;85(5-6):206-10
   PubMed Web of Science ®Google Scholar
• Yu LC, Lu JT, Huang YH, Involvement of endogenous opioid systems in nociceptin-induced spinal antinociception in rats. Brain Res 2002;945(1):88-96
   PubMed Web of Science ®Google Scholar
• Nazzaro C, Rizzi A, Salvadori S, UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice. Peptides 2007;28(3):663-9
   PubMed Web of Science ®Google Scholar
• Khroyan TV, Polgar WE, Orduna J, Activity of new NOP receptor ligands in a rat peripheral mononeuropathy model: potentiation of morphine anti-allodynic activity by NOP receptor antagonists. Eur J Pharmacol 2009;610(1-3):49-54
   PubMed Web of Science ®Google Scholar
• Fu X, Wang YQ, Wu GC. Involvement of nociceptin/orphanin FQ and its receptor in electroacupunctureproduced anti-hyperalgesia in rats with peripheral inflammation. Brain Res 2006;1078:212-8
   PubMed Web of Science ®Google Scholar
• Tamai H, Sawamura S, Takeda K, Anti-allodynic and anti-hyperalgesic effects of nociceptin receptor antagonist, JTC-801, in rats after spinal nerve injury and inflammation. Eur J Pharmacol 2005;510(3):223-8
   PubMed Web of Science ®Google Scholar
• Khroyan TV, Polgar WE, Jiang F, Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists. J Pharmacol Exp Ther 2009;331(3):946-53
   PubMed Web of Science ®Google Scholar
• Devine DP, Reinscheid RK, Monsma FJ Jr, The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res 1996;727(1-2):225-9
   PubMed Web of Science ®Google Scholar
• Murphy NP, Ly HT, Maidment NT. Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience 1996;75(1):1-4
   PubMed Web of Science ®Google Scholar
• Murphy NP, Lee Y, Maidment NT. Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res 1999;832(1-2):168-70
   PubMed Web of Science ®Google Scholar
• Hao JX, Wiesenfeld-Hallin Z, Xu XJ. Lack of cross-tolerance between the antinociceptive effect of intrathecal orphanin FQ and morphine in the rat. Neurosci Lett 1997;223(1):49-52
   PubMed Web of Science ®Google Scholar
• Jhamandas KH, Sutak M, Henderson G. Antinociceptive and morphine modulatory actions of spinal orphanin FQ. Can J Physiol Pharmacol 1998;76(3):314-24
   PubMed Web of Science ®Google Scholar
• Abdulla FA, Smith PA. Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons. J Neurosci 1998;18(23):9685-94
   PubMed Web of Science ®Google Scholar
• Kotlińska J, Suder P, Legowska A, Orphanin FQ/nociceptin inhibits morphine withdrawal. Life Sci 2000;66(8):PL119-23
   PubMed Web of Science ®Google Scholar
• Ciccocioppo R, Angeletti S, Panocka I, Nociceptin/orphanin FQ and drugs of abuse. Peptides 2000;21(7):1071-80
   PubMed Web of Science ®Google Scholar
• Toll LR, Khroyan TV, Polgar W, Comparison of the anti-nociceptive and anti-rewarding profiles of novel bifunctional nociceptin/orphanin FQ receptor (NOPr)-mu opioid receptor (MOPr) ligands: implications for therapeutic applications. J Pharmacol Exp Ther 2009, published online 22 September 2009, doi:10.1124/jpet.109.157446
   Google Scholar
• Induru RR, Davis MP. Buprenorphine for neuropathic pain: targeting hyperalgesia. Am J Hosp Palliat Care 2009, published online 7 August 2009, doi:10.1177/1049909109341868
   Google Scholar
• Chung S, Pohl S, Zeng J, Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance. J Pharmacol Exp Ther 2006;318(1):262-7
   PubMed Web of Science ®Google Scholar
• Sandrini M, Vitale G, Pini LA, Nociceptin/orphanin FQ prevents the antinociceptive action of paracetamol on the rat hot plate test. Eur J Pharmacol 2005;507(1-3):43-8
   PubMed Web of Science ®Google Scholar
• D'Agostino B, Marrocco G, De Nardo M, Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux. Br J Pharmacol 2005;144(6):813-20
   PubMed Web of Science ®Google Scholar
• Oyama T, Sakana K. Antipruritics. US2008103162A1; 2008
   Google Scholar
• Osi Pharmaceutical. (2-carboxamido)(3-amino)thiophene compounds. US7524859B2; 2009
   Google Scholar
• Culpepper L. Generalized anxiety disorder and medical illness. J Clin Psychiatry 2009; 70:(Suppl 2):20-4
   PubMed Web of Science ®Google Scholar
• Roy-Byrne PP, Davidson KW, Kessler RC, Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry 2008;30(3):208-25
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9(2):105-21
   PubMed Web of Science ®Google Scholar
• Goeldner C, Reiss D, Wichmann J, Activation of nociceptin opioid peptide (NOP) receptor impairs contextual fear learning in mice through glutamatergic mechanisms. Neurobiol Learn Mem 2009;91(4):393-40
   PubMed Web of Science ®Google Scholar
• Vanderah TW, Raffa RB, Lashbrook J, Orphanin-FQ/nociceptin: lack of anti nociceptive, hyperalgesic or allodynic effects in acute thermal or mechanical tests following intracerebroventricular or intrathecal administration to mice or rats. Eur J Pain 1998;2(3):267-78
   PubMed Web of Science ®Google Scholar
• Dietis N, Guerrini R, Calo G, Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth 2009;103(1):38-49
   PubMed Web of Science ®Google Scholar
• Arduin M, Spagnolo B, Calò G, , Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with calpha,alpha-dialkylated amino acids. Bioorg Med Chem 2007;15(13):4434-43
   PubMed Web of Science ®Google Scholar
• Kyle D, Goehring RR. Triazospiro compounds having nociceptin receptor affinity US2004132757A1; 2004
   Google Scholar